TYRATyra Biosciences, IncSigning up patients
Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer
Low-grade NMIBC · FGFR Gene Amplification · FGFR Gene Alterations · FGFR3 Gene Alteration · FGFR3 Gene Mutation · FGFR3 Gene Fusions
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2
- Patients
- 90 (planned)
- Started
- Jun 27, 2025
- Main results expected
- Feb 2028
- Fully finished
- Sep 2028
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
To assess the efficacy of TYRA-300 in LG IR-NMIBC participants
Measured over: at 3 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT06995677 · record last updated 2026-10-27 · checked 2026-11-09 15:47 UTC